Vol 43, No 1 (2012)
Experts’ Guidelines
Published online: 2012-01-01

open access

Page views 195
Article views/downloads 2792
Get Citation

Connect on Social Media

Connect on Social Media

Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma for 2012

Anna Dmoszyńska1, Adam Walter-Croneck1, Joanna Mańko1, Lidia Usnarska-Zubkiewicz2, Beata Stella-Hołowiecka3, Jan Walewski4, Grzegorz Charliński5, Wiesław Wiktor Jędrzejczak5, Elżbieta Wiater5, Ewa Lech-Marańda6, Dominik Dytfeld7, Mieczysław Komarnicki7, Krzysztof Giannopoulos8, Krzysztof Jamroziak9, Tadeusz Robak9, Artur Jurczyszyn10, Aleksander Skotnicki10
DOI: 10.1016/S0001-5814(12)31003-7
Acta Haematol Pol 2012;43(1):7-47.

Abstract

New drugs introduced in recent years to the therapy of multiple myeloma (MM) patients allow to obtain therapeutic responses in the majority of patients. Therapeutic regimens based on thalidomide and on bortezomib are recommended to the therapy as well of patients being candidates to high dose therapy and autologous stem cell transplantation as unfit to such procedure. In relapsed/refractory patients regimens based on lenalidomide are recommended. An integral part of MM therapy is maintenance therapy and supportive care. In this article we described also therapeutic recommendation for other plasmocytic dyscrasia.

Article available in PDF format

View PDF (Polish) Download PDF file